ChemDiv congratulates our colleagues from St. Jude Children’s Research Hospital who have published a new article regarding The von Hippel–Lindau (VHL) tumor and VHL ligand-binding assays.
They developed the first small-molecule-based high-affinity VHL fluorescent probe BODIPY FL VH032, with a Kd of 3.01 nM, for a time-resolved fluorescence resonance energy-transfer assay.
They reported that this new assay is sensitive, selective, resistant to assay interference, and capable of characterizing VHL ligands with a wide range of affinities. It is also suitable for VHL ligand identification and characterization with high-throughput screening.
We are especially proud that researchers used our custom-assembled alpha-helix library for pilot screening with the BODIPY FL VH032 (5)-mediated VHL TR-FRET Binding Assay.
Follow the link and read the full article⬇ https://pubs.acs.org/doi/abs/10.1021/acsomega.0c05221/